Zimmer Biomet and Amedica have seen steady growth over the past two years. Here is a comparison of the companies' financial reports, according to The Leger Gazette.
When comparing insider and institutional ownership, 86.5 percent of Zimmer Biomet's shares are owned by institutional investors while 5.6 percent of Amedica shares are owned by institutional investors.
Zimmer Biomet also reported higher revenues and earnings compared to Amedica. In 2017, Zimmer Biomet reported $7.82 billion in revenues, and Amedica reported $15.23 million. The two companies also had stark differences in net income. Zimmer Biomet reported $1.81 billion while Amedica saw a $14.76 million loss in net income.
Amedica's beta is at 1.36, suggesting its stock price is 236 percent less volatile. In comparison, Zimmer Biomet's beta is +1.13, meaning it is 13 percent more volatile.
In all, Zimmer Biomet beat Amedica on 13 of 16 factors used to compare the companies.